| Category | Sensitive Skincare |
| Founded | 2010 |
| Headquarters | Kunming |
| Listing | Listed via parent Botanee · 300957.SZ (ChiNext, Mar 2021) |
| Latest revenue | Parent Botanee FY2025 revenue RMB 5.36bn, net profit RMB 506m |
| Hero SKUs | Soothing Repair Cream / Light Sunscreen |
Brand History
Winona was launched in Kunming in 2010 by Botanee, whose founding team came out of Dihon Pharmaceutical and brought clinical habits into skincare: dermatologist-led observational studies first, then distribution starting from hospitals and pharmacies. Its actives are Yunnan botanicals — purslane for soothing, prickly pear seed oil for barrier repair.
Botanee listed on ChiNext in March 2021 (300957) and briefly crossed a RMB 100bn valuation, earning the 'first Chinese cosmeceutical stock' label. Distribution then shifted online to Tmall and Douyin, with extensions such as Winona Baby. Group revenue rose from RMB 5.52bn in 2023 to RMB 5.74bn in 2024 before falling to RMB 5.36bn in 2025 (-6.58%) as the efficacy segment crowded, while cost discipline lifted core profit by 48.22%.
Hero Products
Three-Year Financials
| Year | Revenue (RMB bn) | YoY | Net profit (RMB bn) |
|---|---|---|---|
| 2023 | 55.22 | +10.15% | 7.57 |
| 2024 | 57.36 | +3.87% | 5.03 |
| 2025 | 53.59 | -6.58% | 5.06 |
Brand-level：Winona generated roughly RMB 4bn in 2025, down year on year and about 80% of group revenue; sub-brands such as Winona Baby remain in cultivation.
Source：Botanee annual reports 2023-2025; C2CC brand ranking
Company Coverage
- 2026-04Botanee FY2025: RMB 5.36bn revenue, core profit +48.22%
Revenue fell for a second year while cost control and mix lifted core profit.
Source：Annual report - 2025-10OTC pharmacy network keeps expanding
Pharmacies are treated as credibility plus incremental traffic, merchandised as skin solutions.
Source：Company filings / media - 2025-08Multi-brand cultivation continues
Winona Baby and the premium line carry the second-curve task but remain a small share of revenue.
Source：Company filings